Kenalog and Failure to thrive - a phase IV clinical study of FDA data

Summary:

Failure to thrive is reported as a side effect among people who take Kenalog (triamcinolone acetonide), especially for people who are female, 60+ old, also take Ativan, and have Aseptic necrosis.

The phase IV clinical study analyzes which people have Failure to thrive when taking Kenalog. It is created by eHealthMe based on reports of 10,533 people who have side effects when taking Kenalog from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Failure to thrive?

Failure to thrive (inadequate weight gain and physical growth in children) is found to be associated with 772 drugs and 1,167 conditions by eHealthMe. Check the latest studies of Failure to thrive.

On Jul, 14, 2026

10,533 people reported to have side effects when taking Kenalog.
Among them, 13 people (0.12%) have Failure to thrive.

Among these 13 people:

What is the gender of people who have Failure to thrive when taking Kenalog? *

female: 61.54 %
male: 38.46 %

What is the age of people who have Failure to thrive when taking Kenalog? *

What are other drugs people take besides Kenalog? *

What are other side effects people have besides Failure to thrive? *

Anaemia (lack of blood): 9 people, 69.23%
High Blood Pressure: 8 people, 61.54%
Aortic Valve Incompetence: 8 people, 61.54%
Mitral Valve Incompetence (inefficient heart valve): 8 people, 61.54%
Atelectasis (partial or complete collapse of the lung): 8 people, 61.54%
Fatigue (feeling of tiredness): 8 people, 61.54%
Swallowing Difficulty: 8 people, 61.54%
Pneumonia: 8 people, 61.54%
Sepsis (a severe blood infection that can lead to organ failure and death): 7 people, 53.85%
Fever: 7 people, 53.85%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 4 people, 30.77%
Immunodeficiency Disorders: 4 people, 30.77%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 4 people, 30.77%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 4 people, 30.77%
Wound Complication: 1 person, 7.69%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 7.69%
Panic Disorder: 1 person, 7.69%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 7.69%
Joint Pain: 1 person, 7.69%
Headache (pain in head): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and have Failure to thrive?

- Check whether Failure to thrive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kenalog:

Kenalog (10,692 reports)

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Failure to thrive:

Failure to thrive (772 drugs)

Browse all the conditions that are associated with Failure to thrive:

Failure to thrive (1,167 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide (the active ingredients of Kenalog) and Kenalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.